Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
inactivated influenza vaccine-The University of Hong Kong-influenza
- Development stage
- Unknown
- Lead developer
- The University of Hong Kong
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
This entry refers to a specific twice-annual vaccination regimen evaluated by The University of Hong Kong in the RETAIN clinical trial. The strategy involves the administration of inactivated influenza vaccines (IIV) twice a year, utilizing both Northern Hemisphere (NH) and Southern Hemisphere (SH) formulations to provide continuous protection in regions with complex influenza seasonality. The vaccines used in the trial are quadrivalent inactivated influenza vaccines (QIV) manufactured by Sanofi Pasteur, specifically FluQuadri and Vaxigrip. These vaccines contain purified hemagglutinin antigens from four influenza strains (A/H1N1, A/H3N2, and two B lineages). The regimen is designed to address the rapid waning of vaccine-induced immunity in older adults (aged 70-79) by providing a booster effect and updating the strain composition to match circulating viruses in both hemispheres.
- Brand names
- FluQuadriVaxigrip
- Other names
- Twice-annual influenza vaccinationNH and SH influenza vaccine regimenInactivated influenza vaccine (The University of Hong Kong)
02
Targets
HA (Hemagglutinin)
Beyond the preview
Go deeper on inactivated influenza vaccine-The University of Hong Kong-influenza.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on inactivated influenza vaccine-The University of Hong Kong-influenza.